Browse the world's most comprehensive database of hedge fund investor letters, sorted by recent quarter. Access primary source research from leading institutional managers.
Buyside Digest is not affiliated with, and does not endorse, Invenomic Capital Management. This analysis is provided for institutional research purposes only and is not investment advice.
Fund Returns
QTD+25.6%
YTD-3.5%
Annualized+0.0295%
Positioning StanceCAUTIOUS
Market CapAll Cap
Digest Analysis
Quick Take
"The Invenomic Fund underperformed in September due to an extraordinary momentum rally, but remains highly cautious and defensively positioned against what it views as an unsustainable, AI-driven valuation bubble."
Executive Summary
For September 2025, the Invenomic Fund returned -5.63%, underperforming the S&P 1500 Index (+3.42%) due to a historic momentum surge that detracted roughly 4.5% from the fund's short book. Despite the underperformance, Invenomic outlines deep concerns about the current market environment. They highlight that the Shiller CAPE has crossed 40x (approaching the dotcom bubble peak of 44x) and that the Russell 1000 Growth's outperformance of Value is at an all-time 33-month high. The manager believes the AI bubble is showing signs of fundamental decay, as heavy capital expenditures yield low incremental returns, revenue remains anemic, and aggressive late-90s style accounting is emerging. Consequently, the fund is positioned defensively, maintaining a 19.8% average net exposure (112.6% long, -92.8% short).
Unlock Full Institutional Analysis
Sign in or create a free account to unlock full commentary, extracted equity pitches, and direct outbound manager source links with your 3 quarterly credits.
Algorithmic conviction, macroeconomic posture, and risk appetite signals extracted from this quarterly letter with qualitative explanations.
Signal Matrix
Market Conviction
90%
CautiousHigh
High Conviction (90%)
High-conviction positioning: The Invenomic Fund underperformed in September due to an extraordinary momentum rally, but remains highly cautious and defensively positioned against what it views as an unsustaina...
Growth Outlook
20%
BearishBullish
Bearish (20%)
Market outlook remains low conviction: The Invenomic Fund underperformed in September due to an extraordinary momentum rally, but remains highly cautious and defensively positioned against what it views as an unsustaina...
Risk Appetite
20%
DefensiveAggressive
Defensive (20%)
Risk appetite posture is low conviction: The Invenomic Fund underperformed in September due to an extraordinary momentum rally, but remains highly cautious and defensively positioned against what it views as an unsustaina...
Capital Deployment
50%
De-riskingDeploying
Net Neutral (50%)
Manager actively deployed capital into high-conviction opportunities. The Invenomic Fund underperformed in September due to an extraordinary momentum rally, but remains highly cautious and defensively positioned against what it views as an unsustaina...
Forward Guidance
40%
CautiousExpansionary
Neutral (40%)
Forward guidance signal: The Invenomic Fund underperformed in September due to an extraordinary momentum rally, but remains highly cautious and defensively positioned against what it views as an unsustaina...
Language Signal
80%
BearishBullish
Bullish (80%)
Tone analysis indicates high conviction language: The Invenomic Fund underperformed in September due to an extraordinary momentum rally, but remains highly cautious and defensively positioned against what it views as an unsustaina...
Perceived Risk
90%
Low RiskElevated
Elevated Risk (90%)
Perceived risk level is evaluated as high conviction. The Invenomic Fund underperformed in September due to an extraordinary momentum rally, but remains highly cautious and defensively positioned against what it views as an unsustaina...
Opportunity Density
30%
ScarceAbundant
Scarce (30%)
Opportunity density index indicates low conviction actionable entry points. The Invenomic Fund underperformed in September due to an extraordinary momentum rally, but remains highly cautious and defensively positioned against what it views as an unsustaina...
Time Horizon
70%
Short-TermLong-Term
Decade+ (70%)
Investment time horizon reflects a above average conviction orientation. The Invenomic Fund underperformed in September due to an extraordinary momentum rally, but remains highly cautious and defensively positioned against what it views as an unsustaina...